Study of 225Ac-TR2205 for triple-negative breast cancer
Part of Cancer clinical trials.
This trial tests a new radioactive drug called 225Ac-TR2205 for people with triple-negative breast cancer that has spread. The goal is to see if it is safe and tolerable. It may be an option if you have tried at least two other treatments, including one for metastatic disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have triple-negative breast cancer confirmed by biopsy.
- Your cancer has spread and you have had at least two prior treatments, with at least one for metastatic disease.
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, MR001, for people with triple-negative breast cancer that has come back or spread. It's for those who've already tried at least one type of treatment.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial tests a new drug called LBL-024, either alone or with other medicines, for people with triple negative breast cancer. It aims to see if the drug can shrink tumors and how safe it is.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
This study tests a new imaging agent that targets a protein called ACE, which may be found in triple-negative breast cancer. The imaging will help doctors see the cancer more clearly and could aid in planning your treatment.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
Hear when a new Advanced Metastatic Triple-negative Breast Cancer (mTNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.